Navigation Links
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
Date:9/25/2008

LAUSANNE, Switzerland, September 25 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Once approved, Decapeptyl(R) 6-month formulation will be marketed by Debiopharm's partners, such as Ipsen in most European Union countries.

"This submission in Europe of our first 6-month-formulation for the treatment of prostate cancer is another demonstration of Debiopharm's commitment to supporting and enhancing the life of cancer patients. With an injection every 24 weeks, patients will benefit from increased convenience and comfort," said Kamel Besseghir, CEO of Debiopharm S.A. "Furthermore, upon approval, our newly built production line will be ready to manufacture the drug for worldwide distribution."

The MAA for Decapeptyl(R) 6 month formulation is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin.

About Decapeptyl(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- and 3-month sustained release formulation of triptorelin pamoate in Europe and
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
4. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
5. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
6. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dec. 1 CCS Medical, Inc. a leadin... today announced that it has received approval fro...of Delaware (the "Court") for its bidding procedur...ale of substantially all of its assets. ,, Purs...t approved bidding procedures for the sale of subs...
(Date:12/1/2009)... 1 CEL-SCI Corporation (...nd a developer of vaccines and therapeutics for th... announced today that it has retained the services...n (CRO) to run CEL-SCI,s upcoming Phase III clinic...with the Company,s lead product candidate, Multiki...
(Date:12/1/2009)... Dec. 1 MedQuist Inc. ...-enabled clinical documentation services, today an...dial Design, Inc. has been integrated with SpeechQ...cognition system. The solution is being demonstrat...SNA) convention November 29 through December 2. ...
Breaking Medicine Technology:CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 1Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 2EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 1EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 2EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 3EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 4YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 1YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 2YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 3YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 4
...-Company to Host Conference Call at 9:00 a.m. EDT-... Corp. (Nasdaq: MEMY ) today announced top-line d...d, placebo-controlled Phase 2a study,of MEM 1003, ...zheimer,s,disease. The trial enrolled 183 subjects... 40 centers in the United States and included mono...
...ORLANDO, Fla., Oct. 13 Acutely ill, hospitalized,...rovement in symptoms,after taking INVEGA(TM) (pali...SEROQUEL(R)(a) (quetiapine) and placebo. Symptom i...ve days into therapy and continued,through the end...inary data,presented today at the 20th Annual U.S....
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7
(Date:12/1/2009)...ESEARCH TRIANGLE PARK, N.C., Dec. 1 /PRNewswire/ -...001 and have expanded over the years serving the t...ility which was originally set up in an area of 20...ces, as part of the suite of services by Max Neema... a valuable offering. ,, The pharmacy inventory...
(Date:12/1/2009)...HINGTON, Dec. 1 Individ...ore likely than those with traditional coverage to...be more engaged in wellness programs, and to be mo...ter in holding down costs, according to survey res...nefit Research Institute (EBRI). ,, At the sam...
(Date:12/1/2009)...RT LAUDERDALE, Fla., Dec. 1 OrbusN...ollment in the randomized clinical trial of the Co...Stent). ,, A prospective, randomized, multicent...f an ablu M inal sirolimus coat ED bio- E n... to 20 sites in Asia, Australia, Europe and South ...
(Date:12/1/2009)...ents in California are unable to successfully obta...ospitals despite recent state legislation intended... study. , Posing as low-income uninsured patient...than one-third of the hospitals they approached an...an those allowed under California law, according t...
(Date:12/1/2009)... Lumension announces general availability... to deliver end-to-end endpoint management capabil...management console architecture. , ...-- Lumension, a global leader in endpoint manageme...® Endpoint Management and Security Suite (LEMS...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
...pril 22 Halo Pharmaceutical, this week announced ...rom The Provident Bank to expand its operations. ,... held full-service, specialty pharmaceutical compa...ed industries. , , "Provident is a respected loc...
...nd mother teams up with the March of Dimes and san...ation campaign , , WHITE PLAINS, N.Y. and SWIFTWA...to hear their baby,s first babbles and coos, there... commonly known as whooping cough. Ms. Lopez has j...
...22 ResMed Inc. (NYSE: RMD ), announced today th...esults for the third quarter and nine months of fi...lease with ResMed,s results will be issued after 1...rence call is scheduled to begin at 1:30 p.m. Paci...
...s larger trials needed to assess therapy over long... News) -- Acupuncture reduces severe dry mouth (xe...ead and neck cancer, a small pilot study suggests....e dental oncology department at the University of ...
...esearch, study finds older people taking NSAIDs mo... April 22 (HealthDay News) -- Research has suggest... disease might want to take daily doses of painkil...ent dementia?, the answer based on our study woul...
...itish Columbia researchers have discovered a "mole... blood stem cell transplants, a procedure currentl...,s lymphoma and aplastic anemia. , During a blood... new blood. The stem cells then need to travel to ...
Other Medicine News:Health News:Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank 2Health News:Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs 2Health News:Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs 3Health News:Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs 4Health News:Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs 5Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Acupuncture Cuts Dry Mouth in Cancer Patients 2Health News:Painkillers May Not Protect Against Dementia 2Health News:Painkillers May Not Protect Against Dementia 3
Bra With Cups
Bandeau Bra
Medical Cotton Bra
Compression Bra
Medicine Products: